Journal article

A blood-based predictor for neocortical A beta burden in Alzheimer's disease: results from the AIBL study

SC Burnham, NG Faux, W Wilson, SM Laws, D Ames, J Bedo, Ai Bush, JD Doecke, KA Ellis, R Head, G Jones, H Kiiveri, RN Martins, A Rembach, CC Rowe, O Salvado, SL Macaulay, CL Masters, VL Villemagne

Molecular Psychiatry | NATURE PUBLISHING GROUP | Published : 2014


Awarded by Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant)

Awarded by NIH

Funding Acknowledgements

Core funding for the study was provided by the CSIRO Flagship Collaboration Fund, and the Science and Industry Endowment Fund (SIEF) in partnership with Edith Cowan University (ECU), Mental Health Research institute (MHRI), Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, CogState, Hollywood Private Hospital, Sir Charles Gardner Hospital. The study also receives funding from the National Health and Medical Research Council (NHMRC), the Dementia Collaborative Research Centres programme (DCRC), The McCusker Alzheimer's Research Foundation and Operational Infrastructure Support from the Government of Victoria. Faux NG is supported by a National Health and Medical Research Council training fellowship. Laws SM is supported by research fellowships from Edith Cowan University. Bush AI is supported by the NHMRC by a programme grant and an Australian Fellowship. We wish to thank the participants in AIBL for their commitment and dedication to help in advance research into the early detection and causation of AD, and the clinicians who referred patients to the study. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences; AstraZeneca; Bayer HealthCare; BioClinica; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals; Eli Lilly and Company; F Hoffmann-La Roche and its affiliated company Genentech; GE Healthcare; Innogenetics, NV; Janssen Alzheimer Immunotherapy Research and Development; Johnson & Johnson Pharmaceutical Research & Development; Medpace; Merck & Co.; Meso Scale Diagnostics; Novartis Pharmaceuticals Corporation; Pfizer; Servier; Synarc and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( The grantee organisation is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514.